PetMed Express (PETS) Aperçu de l'action
PetMed Express, Inc. et ses filiales opèrent en tant que pharmacie pour animaux de compagnie aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
PETS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PetMed Express, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.80 |
| Plus haut sur 52 semaines | US$4.10 |
| Plus bas sur 52 semaines | US$1.57 |
| Bêta | 0.77 |
| Variation sur 1 mois | -20.00% |
| Variation sur 3 mois | -27.42% |
| Variation sur 1 an | -47.37% |
| Variation sur 3 ans | -86.91% |
| Variation sur 5 ans | -94.92% |
| Évolution depuis l'introduction en bourse | 44.00% |
Nouvelles et mises à jour récentes
PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaPETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).Recent updates
PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaPETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).PETS: Rural King Partnership Will Shape Future Margins And Earnings Multiple
Analysts have trimmed their price target on PetMed Express to reflect a fair value update from $3.00 to $2.15 as they incorporate more moderate expectations for revenue contraction, profit margins, and a higher future P/E multiple into their models. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King retail stores and digital platforms, expanding access to prescription medications, preventatives and pet health products for Rural King customers (Key Developments).Getting In Cheap On PetMed Express, Inc. (NASDAQ:PETS) Is Unlikely
It's not a stretch to say that PetMed Express, Inc.'s ( NASDAQ:PETS ) price-to-sales (or "P/S") ratio of 0.3x right now...Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%
To the annoyance of some shareholders, PetMed Express, Inc. ( NASDAQ:PETS ) shares are down a considerable 26% in the...
Cost Cuts And Digital Upgrades Will Strain Future Margins
Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.PetMed Express: Dip Or Rip, A Buy After Earnings
Summary PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside. Even if it takes time to take shape, improvements in PetMed's operating performance could ultimately send the stock back to prices north of $15 per share. Read the full article on Seeking AlphaWe Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding
PetMed Express, Inc. ( NASDAQ:PETS ) shares have retraced a considerable 28% in the last month, reversing a fair amount...PetMed Express: Why (And Why Not) The Rebound Could Continue
Summary PetMed Express (PETS) surged 35.8% on Nov. 7, following the online pet pharmacy's latest quarterly earnings release. Despite the massive post-earnings surge, further upside may lie ahead, if the turnaround continues. PetMed's management team is implementing a strategy change, not just cost-cutting measures, to continue improving the company's fiscal performance. Although many risks and uncertainties remain, given the outsized impact further improvements could have on the PETS stock price, at the very least add it to your watchlist. Read the full article on Seeking AlphaOptimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking
PetMed Express, Inc. ( NASDAQ:PETS ) shares have had a really impressive month, gaining 28% after a shaky period...PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
There's been a notable change in appetite for PetMed Express, Inc. ( NASDAQ:PETS ) shares in the week since its...PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates
PetMed Express, Inc. ( NASDAQ:PETS ) last week reported its latest annual results, which makes it a good time for...PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the Dividend Discount Model, PetMed Express fair value estimate is US$7.95 Current share price of...A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)
Key Insights PetMed Express' estimated fair value is US$11.85 based on 2 Stage Free Cash Flow to Equity Current share...PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30
The board of PetMed Express, Inc. ( NASDAQ:PETS ) has announced that it will pay a dividend of $0.30 per share on the...Rendement pour les actionnaires
| PETS | US Specialty Retail | US Marché | |
|---|---|---|---|
| 7D | 4.7% | -0.4% | 2.0% |
| 1Y | -47.4% | 6.7% | 23.3% |
Rendement vs Industrie: PETS a sous-performé le secteur US Specialty Retail qui a rapporté 6.7 % au cours de l'année écoulée.
Rendement vs marché: PETS a sous-performé le marché US qui a rapporté 23.3 % au cours de l'année écoulée.
Volatilité des prix
| PETS volatility | |
|---|---|
| PETS Average Weekly Movement | 7.0% |
| Specialty Retail Industry Average Movement | 7.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: PETS n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PETS a diminué de 14% à 7% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 189 | Leslie C. Campbell | www.1800petmeds.com |
PetMed Express, Inc. et ses filiales sont des pharmacies pour animaux de compagnie aux États-Unis. La société commercialise des médicaments sur ordonnance et en vente libre, des produits de santé et d'autres fournitures pour chiens, chats et chevaux. Elle propose des médicaments et des fournitures en vente libre, tels que des produits contre les puces et les tiques, des produits pour le soin des os et des articulations, des vitamines, des friandises, des suppléments nutritionnels, des produits d'hygiène et des articles ménagers pour animaux de compagnie, ainsi que des médicaments sur ordonnance, notamment des vermifuges, des antipuces et des antitiques, des médicaments contre l'arthrite, la dermatite, la thyroïde, le diabète, la douleur, la tension artérielle et le cœur, et d'autres médicaments spécialisés, ainsi que des substituts génériques.
PetMed Express, Inc. Résumé des fondamentaux
| PETS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$37.85m |
| Bénéfices(TTM) | -US$57.29m |
| Recettes(TTM) | US$179.02m |
Le site PETS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PETS compte de résultat (TTM) | |
|---|---|
| Recettes | US$179.02m |
| Coût des recettes | US$128.81m |
| Marge brute | US$50.22m |
| Autres dépenses | US$107.50m |
| Les revenus | -US$57.29m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.72 |
| Marge brute | 28.05% |
| Marge bénéficiaire nette | -32.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de PETS?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/17 07:48 |
| Cours de l'action en fin de journée | 2026/06/17 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
PetMed Express, Inc. est couverte par 15 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Erin Wilson Wright | BofA Global Research |
| Kristine Koerber | Citizens JMP Securities, LLC |
| David Westenberg | CL King & Associates, Inc. |